BAAR, Switzerland, January 03, 2025--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday ...

Novocure (NASDAQ: NVCR) announced today that management will participate in the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive ...

Piper Sandler raised the firm’s price target on Novocure (NVCR) to $42 from $28 and keeps an Overweight rating on the shares. The firm thinks the catalyst path for Novocure shares screens more ...

Novocure (NASDAQ: NVCR) announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive Officer, ...

Evercore ISI raised the firm’s price target on Novocure (NVCR) to $46 from $34 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and ...

Check Out Our Latest Research Report on NVCR NovoCure Trading Down 3.4 % Shares of NASDAQ NVCR opened at $30.06 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt ...

Novocure Ltd . (NASDAQ:NVCR), a pioneering oncology medical technology company valued at $3.62 billion, has been making waves in the cancer treatment sector with its innovative Tumor Treating ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and NovoCure (NVCR – Research Report). Pick the best stocks ...

Novocure has gained clearance from the US Food and Drug Administration (FDA) for the new head flexible electrode (HFE) transducer arrays for use with Optune Gio, a wearable for treating adults ...

Over the last year, Novocure Limited share price has been traded in a range of 19.77, hitting a high of 34.10, and a low of 14.33. Novocure Limited is listed on the CBOE trading with ticker code ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...